Medicine
Kebilidi 560000000000 GC/mL oral suspension
Kebilidi 560000000000 GC/mL oral suspension is a prescription medicine containing Eladocagene exuparvovec for intracerebral use, marketed by PTC Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store and transport frozen at ≤-65°C (-85°F). If not used immediately, store…
Key facts
- Active ingredient (INN)
- Eladocagene exuparvovec
- Brand
- Kebilidi
- Strength
- 560000000000 GC/mL
- Dosage form
- Oral suspension
- Route
- Intracerebral
- Packs
- 1 vial
- Marketing authorisation holder
- PTC Therapeutics
- Manufacturer
- PTC Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store and transport frozen at ≤-65°C (-85°F). If not used immediately, store at room temperature (up to 25°C [77°F]) and use within 6 hours of starting product thaw.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AB26 Eladocagene exuparvovec
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 November 2024
- Identifiers
- RxCUI 2698771, 2698778DailyMed set ID 9d6a6401-c6b5-4f29-af11-67707d249482NDC 52856-601Application BLA125722
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / .5 mL in 1 vial, glass | 52856-601-01 | PTC Therapeutics | 13 November 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Eladocagene exuparvovec is a prescription medicine indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. It is available as oral suspension for intracerebral use. MedsAcross supplies Eladocagene exuparvovec for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Eladocagene exuparvovecFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KEBILIDI prescribing information (PTC Therapeutics) · U.S. National Library of Medicine, DailyMed
- Upstaza: European public assessment report (EPAR) · European Medicines Agency
Need Kebilidi 560000000000 GC/mL oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.